Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Epigenomics
; 16(5): 293-308, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38356412
ABSTRACT
Background:
Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options. Eribulin, a chemotherapeutic drug, induces epigenetic changes in cancer cells, suggesting a unique mechanism of action. Materials &methods:
MDA-MB 231 cells were treated with eribulin and paclitaxel, and the samples from 53 patients treated with neoadjuvant eribulin were compared with those from 14 patients who received the standard-of-care treatment using immunohistochemistry.Results:
Eribulin treatment caused significant DNA methylation changes in drug-tolerant persister TNBC cells, and it also elicited changes in the expression levels of epigenetic modifiers (DNMT1, TET1, DNMT3A/B) in vitro and in primary TNBC tumors.Conclusion:
These findings provide new insights into eribulin's mechanism of action and potential biomarkers for predicting TNBC treatment response.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Metilación de ADN
/
Neoplasias de la Mama Triple Negativas
/
Furanos
/
Policétidos Poliéteres
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Epigenomics
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos